NARAC 2017 Update in Rhinology & Allergy

February 9, 2017 to February 11, 2017

NARAC 2017 Update in Rhinology & Allergy is an annual meeting dually representing Allergists and ENTs with the goal of improving the accuracy of diagnosis and effectiveness of treatments for allergic and rhinologic diseases.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14 AMA PRA Category 1 Credits(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
This activity is supported in part by independent medical education grants from Acclarent, Greer and Shire



Target Audience


Learning Objectives

At the conclusion of this activity, participants should be able to: 

- Recognize the burden of illness related to severe CRS in association with severe asthma
- Identify appropriate strategies to determine the diagnosis of chronic rhinosinusitis and its subtypes
- Discuss the hypothesized pathophysiologic mechanisms for development of chronic rhinosinusitis       
- Discuss the risks & benefits of novel medical & surgical therapeutic modalities for chronic rhinosinusitis in association with severe asthma 
- Diagnose and treat both upper and lower airway causes of chronic cough including  asthma and CRS
- Develop optimal treatment strategies for moderate to severe allergic rhinitis
- Identify, treat and/or refer appropriate patients for skull base surgery
- Diagnose and treat angioedema of the head and neck

Additional information

NARAC 2017 Update in Rhinology & Allergy
February 9-11, 2017
Puerto Rico

Disclosure Policy 
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All identified conflicts of interest have been resolved.

Michael Blaiss, MD
Consultant: PMD Healthcare, JDP Therapeutics, Stallergenes/Greer, Pfizer

Don Bukstein, MD
Speaker: AstraZeneca, Genentech, Meda, Merck, Novartis, Teva, Circassia, Stallergens/Greer, Mylan, 
PBL Institute
Advisory Committee: Stallergenes/Greer
Independent Contractor: PBL Institute  

Simon Carney, MD
Consultant: Olympus

Rakesh Chandra, MD
Consultant: Johnson & Johnson, Olympus, Meda, IntersectENT, OptiNose, NeilMed

Noam Cohen, MD
Consultant: Bayer, GlaxoSmithKline, AmpliPhi, 480 Biomedical
Speaker: Reckitt Benckiser, Bionorica

David Conley, MD
Consultant: IntersectENT
Speaker: IntersectENT

Ray S. Davis, MD
Consultant: Teva, Meda, Mylan, AstraZeneca, Baxalta, Sunovion
Speaker: Teva, Meda, Mylan, AstraZeneca, 
Advisory Committee: DBV Technology

Robert Kern, MD
Consultant: 480 Biomedical, GlaxoSmithKline, Genentech
Research: NIH

Tonya Laidlaw, MD
Consultant: Chiesi, Allakos, Knopp Biosciences

Rey Panettieri Jr., MD
Consultant: AstraZeneca
Speaker: Boston Scientific, Teva
Advisory Committee: AstraZeneca, Novartis, MedImmune
Research: AstraZeneca, Amgen, Novartis, Theratropix, OncoArendi, Bristol Myers Squibb, Vertex, RIFM

Anju Peters, MD
Speaker: Greer
Advisory Committee: Greer
Research: AstraZeneca, Sanofi

Neil Peters, MD
Speaker: Celgene
Advisory Committee: Celgene

Russell Settipane, MD
Speaker: AstraZeneca, Genentech, Mylan, Meda, Teva, Merck, Stallergenes/Greer, Boehringer Ingelehim
Advisory Committee: AstraZeneca, Teva, Merck, Genentech, Sanofi, ALK, Circassia
Research: Novartis, Genentech, Mylan, Oriel Therapeutics, Teva, Merck, Circassia

Raj Sindwani, MD
Consultant: Medtronic, Olympus, Acclarent

Carl Snyderman, MD
Consultant: SPIWay

Zachary M. Soler, MD
Consultant: Olympus

Ian Witterick, MD
Advisory Committee: Proteocyte Diagnostics

The following have no financial relationships to disclose:
Gustavo Almodovar-Mercado, MD
Jose Busquets, MD
Alan Gaines, MD
Ginny Loiselle
Cristina Ramos, MD
Timothy Smith, MD
Andrew White, MD
Education Staff/Committee have no financial relationships to disclose, except as may be listed above.

Course summary
Available credit: 
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Attendance
Course opens: 
Course expires: 
Event starts: 
02/09/2017 - 4:30pm CST
Event ends: 
02/11/2017 - 2:00pm CST

Available Credit

  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Attendance
Please login or create an account to take this course.